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Abstract: Currently, there is limited information on the clinical
characteristics of breast cancer patients with insulin resistance. Hence,
the purpose of this study was to investigate the association between
insulin resistance and clinicopathological factors in newly diagnosed
breast cancer patients without diabetes.
We assessed 760 patients with breast cancer treated between 2012
and 2014. We compared the clinicopathological characteristics between
patients with and without insulin resistance using univariate and multi-
variate analyses, including after stratification by menopausal status.
Insulin resistance was defined according to the homeostatic model
assessment of insulin resistance.
Of 760 patients, 26.4% had insulin resistance. Age, menopausal
status, body mass index, tumor size, histologic grade, Ki-67 expression,
and breast cancer subtype significantly differed according to the pre-
sence of insulin resistance. Multivariate analysis revealed that post-
menopausal status and obesity were significantly associated with insulin
resistance. In postmenopausal women, older age, obesity, larger tumor
size, advanced stage, and high proliferative luminal B subtype were
significantly associated with insulin resistance. In contrast, in preme-
nopausal patients, only obesity was related to insulin resistance. Multi-
variate analysis indicated that insulin resistance was independently
correlated with obesity, larger tumor size, and the luminal B/human
epidermal growth factor receptor-2-negative subtype in postmenopausal
but not premenopausal patients.
Insulin resistance was significantly associated with larger tumors
and proliferative luminal B subtype breast cancer in postmenopausal
women only. These findings suggest that insulin resistance could
mechanistically induce tumor progression and might be a good prog-
nostic factor, and that it could represent a therapeutic target in post-
menopausal patients with breast cancer.
(Medicine 95(9):e2825)
Abbreviations: BMI = body mass index, CI = confidence interval,g Seok Park, MD, , MD,
ung Il Kim, MD, PhD
insulin-like growth factor I, IR = insulin resistance, OR = odds
ratio, PR = progesterone receptor, TNM = tumor node metastasis.
INTRODUCTION
M etabolic syndrome is a major health challenge of the 21stcentury. In the United States, the prevalence of metabolic
syndrome has been reported as 33% in the adult population.1
Similarly, 31.3% of the Korean general population reportedly
have metabolic syndrome, and the incidence rate is increasing
yearly.2 Insulin resistance (IR) plays a central role in the
pathophysiology of metabolic syndrome,3 which is character-
ized as a pathological condition where cells fail to respond to
insulin.4
Previous studies have investigated the association between
metabolic syndrome and malignancy. Metabolic syndrome is a
risk factor for several cancers such as breast, colon, and
endometrial cancers.5–8 The mechanisms underlying these
associations are uncertain, but several studies have shown that
IR causes chronic sustained hyperinsulinemia, which presum-
ably plays a role in carcinogenesis.9,10 Some epidemiological
studies have indicated that IR could be a risk factor for the
development of breast cancer,11,12 and these findings were more
significant in postmenopausal women.7,13 Additionally, women
with IR tend to develop more proliferative cancers and present
with a worse prognosis.14 However, despite these hypotheses,
there are limited data concerning the clinicopathological
characteristics of breast cancer patients with IR, particularly
in Asian women.
The purpose of this study was to investigate the prevalence
of IR in breast cancer patients and to examine any
associations between IR and clinicopathological factors in
newly diagnosed breast cancer patients without diabetes. We
also explored the relationship of IR with prognostic factors
according to menopausal status. To our knowledge, this is the
first report to explore these relationships in Asian patients with
breast cancer.
MATERIALS AND METHODS
Study Population
The medical records of 1301 patients who underwent
definitive surgery for breast cancer at the Department of Surgery,
Yonsei University Severance Hospital in Seoul, Korea, between
January 2012 andNovember 2014were reviewed. Of these, 1107
had available serum insulin and glucose data. A total of 215
patients who underwent neoadjuvant chemotherapy or who were
diagnosed with recurrent or metastatic breast cancers at the time
of surgery were excluded. Further, 132 patients with diabetes
were excluded to reduce confounding factors due to metabolicdefined as a fasting plasma glucose level
determined by a previous diagnosis by a
lysis set included 760 patients (Figure 1).
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Nam et al Medicine  Volume 95, Number 9, March 2016This study was approved by the Institutional Review Board
of Yonsei University Severance Hospital (approval number: 4-
2015-0432) and was conducted in accordance with the prin-
ciples described in the Declaration of Helsinki. Because of the
retrospective nature of this study, the institutional review board
waived the need for informed consent.
Assessment of Insulin Resistance
Venous blood samples were taken after8 hours overnight
fasting to measure fasting serum glucose and insulin levels. The
glucose hexokinase method was used for determining fasting
blood glucose levels. The serum insulin level was measured
using an electrochemiluminescence method. The presence of IR
was defined using the homeostatic model assessment of insulin
resistance (HOMA-IR) according to a previous study.16
HOMA-IR levels were calculated as follows:
HOMA-IR¼ fasting plasma insulin level (mIU/mL) fast-
fasting plasma glucose level (mg/dL)/405.
The cut-off score to define IR was HOMA-IR2.0, which
correlated with values75th percentile in our study cohort.17,18
Clinicopathological Parameters
The body mass index (BMI) was defined as the weight (kg)
divided by height (m) squared. According to the World Health
Organization definitions for the Asian population, the subjects
were categorized as normal (BMI, 18.5–24.99 kg/m2) or obese
FIGURE 1. Flow diagram of patient selection.(BMI25 kg/m2).19 Postmenopause was defined as the absence
of menstruation for 12 months or as a serum follicle stimulat-
ing hormone level >40mIU/mL at the time of diagnosis.
2 | www.md-journal.comThe tumor, node, metastasis (TNM) stage was established
according to the criteria of the 7th American Joint Committee
on Cancer Staging manual.20 Histologic grading followed the
Nottingham grading system.21 High-grade ductal carcinoma in
situ (DCIS) was considered as grade III disease, and non-high
grade DCIS was categorized as grade I–II disease.22
The expressions of estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor receptor-2
(HER-2) were immunohistochemically evaluated in formalin-
fixed, paraffin-embedded whole sections of surgically resected
primary breast cancer specimens. Tumors with 1% nuclear-
stained cells were considered ER-positive or PR-positive.23
HER-2 staining was scored from 0 to 3þ according to the
American Society of Clinical Oncology guidelines.24 Strong
(3þ) membranous staining was defined as HER-2-positive,
whereas cases with 0 to 1þ were regarded as HER-2-negative.
Additional fluorescence or silver in-situ hybridization was
conducted in cases of equivocal (2þ) staining, and an HER-2
gene-to-chromosome ratio of 2.0 was designated as HER-2
amplification.25 The breast cancer subtypes were categorized
according to the St. Gallen International Expert Consensus.26
The Ki-67 levels were immunohistochemically measured in
core-needle biopsy or surgical specimens using a primary MIB-
1 antibody (Dako Denmark A/S, Glostrup, Denmark) and
protocols established at the Department of Pathology at our
institution. Using a visual grading system, the Ki-67 index was
scored in the area with the strongest staining by counting the
number of positively stained nuclei and was expressed as a
percentage of total tumor cells. The Ki-67 expression was
measured in core-needle biopsy specimens in 586 cases
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
(80%) and in surgical specimens in 146 cases (20%). Tumors
with 14% nuclear-stained cells were defined as Ki-67-
positive.27 In cases with unavailable Ki-67 data (n¼ 28), the
histologic grade was used to determine the breast cancer sub-
type, and grade III was considered as the high proliferative
breast cancer subtype.28
Statistical Analysis
We compared the mean serum insulin, glucose, and
HOMA-IR values using independent t tests or 1-way analysis
of variance (ANOVA) for continuous variables. The differences
between categorical variables were evaluated using the chi-
squared test; Fisher’s exact test was used if necessary. For IR, a
multivariate logistic regression model was used to calculate the
odds ratio (OR) and 95% confidence interval (CI). All analyses
were conducted using SPSS software version 20.0 (IBM Inc.,
Armonk, NY, and statistical significance was defined as a 2-
tailed P value<0.05.
RESULTS
The mean age at diagnosis was 51.1 10.4 years. The
mean BMI was 23.0 3.1 kg/m2, and IR was detected in 26.4%
of the patients. The mean insulin, glucose, and HOMA-IR levels
were 6.94 5.21mIU/mL, 96.32 9.08mg/dL, and
1.69 1.38, respectively. The breast cancer stage was 0 to 1
in 67.3% of patients, and 24.4% were obese. The ER, PR, HER-
2, and Ki-67 positivity rates were 76.5%, 56.5%, 20.6%, and
37.0%, respectively. According to the subtype, luminal type
breast cancer accounted for 76.7% of patients, and triple-
negative cancer accounted for 13.5%.
The mean insulin, glucose, and HOMA-IR levels according
to clinicopathological characteristics are shown in Table 1. The
mean insulin, glucose, and HOMA-IR levels were significantly
higher in patients aged >50 years, postmenopausal patients,
obese patients, and in those with a higher TNM stage. The mean
insulin andHOMA-IR levels were significantly different accord-
ing to the Ki-67 expression status and breast cancer subtype.
There were no significant differences in the serum levels accord-
ing to the histologic grade, ER status, or HER-2 status.
Based on categorization by the HOMA-IR level, similar
patterns between clinicopathological characteristics and IR
were demonstrated (Table 2). Compared to those without IR,
patients with IR tended to be older (>50 years), postmenopau-
sal, and obese. In particular, obese patients were 2.35 times
more likely to exhibit IR. Additionally, those with a tumor size
>1 cm, high histologic grade, high Ki-76 index, and luminal B/
HER-2-negative subtype were more likely to exhibit IR. Hor-
mone receptor expression and HER-2 status were not associated
with IR, and the TNM stage lost statistical significance when an
arbitrary categorization of IR was applied. Interestingly, there
was no association of individualized ER, PR, or HER-2 with IR;
however, as a combined parameter, the breast cancer subtype
showed a significant association with IR.
Clinicopathological parameters independently associated
with IR according to the multivariate analyses are shown in
Table 3. IR significantly correlated with postmenopausal status
(OR, 1.72; 95% CI, 1.21–2.43), obesity (OR, 3.04; 95% CI,
2.12–4.37), and luminal B/HER-2-negative subtype (OR, 1.88;
95% CI, 1.13–3.14). When individualized breast cancer sub-
type factors such as ER, PR, HER-2, and Ki-67 status were used
Medicine  Volume 95, Number 9, March 2016for the analysis instead of subtype, the postmenopausal status,
obesity, and positive Ki-67 expression were significantly
associated with IR.
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stratification by menopause, are shown in Table 4. In post-
menopausal women, age, BMI, tumor size, TNM stage, HER-2
status, and Ki-67 expression status were significantly different
according to the presence of IR. Furthermore, in postmenopau-
sal women, a higher proportion of patients with IR had the
luminal B/HER-2-negative subtype, as compared with preme-
nopausal women with IR. In premenopausal patients, only BMI
was significantly different according to IR status.
The multivariate analyses to identify factors related to IR
in postmenopausal women are shown in Table 5. In postme-
nopausal patients, IR was significantly correlated with obesity
(OR, 2.00; 95% CI, 1.23–3.26), higher tumor burden (OR,
1.83; 95% CI, 1.08–3.11), and luminal B/HER-2-negative
subtype (OR, 2.97; 95% CI, 1.39–6.33). In premenopausal
patients, only obesity was associated with IR (OR, 5.32; 95%
CI, 2.99–9.50). Multivariate analysis according to subtype-
related factors revealed that obesity, large tumor size, ER
positivity, and Ki-67 positivity were significantly correlated
with IR, and that HER-2-positivity was inversely associated
with IR (data not shown).
DISCUSSION
The present study demonstrated that IR was significantly
correlated with obesity, postmenopausal status, and high pro-
liferative luminal B/HER-2-negative subtype in patients with
breast cancer. Obesity is a major contributor to metabolic
syndrome3 and is associated with high levels of circulating
insulin and an increased risk of developing breast cancer, and
obese patients with breast cancer are known to have a poor
prognosis.5 Hyperinsulinemia caused by IR in obese patients is
thought to contribute to carcinogenesis, although the potential
mechanisms involved are unknown.3,14
Ki-67 is a nuclear antigen found in proliferating cells, and
is therefore useful as a cellular proliferation marker.29 In our
study, IR was positively correlated with Ki-67 expression.
Insulin has diverse metabolic functions, acts as a growth factor
influencing cell proliferation,9,30 and has a mitogenic function
in normal mammary tissue, as well as in breast cancer cells.14
The molecular mechanisms for these associations are unknown,
but several possible mechanisms have been proposed. Insulin
has been found to stimulate the synthesis of insulin-like growth
factor I (IGF-I) and to weakly bind to the IGF-I receptor. In turn,
this insulin/IGF-I pathway could trigger signaling pathways
downstream of the mitogenic-activated protein kinase and
phosphoinositide-3 kinase/Akt pathways, 2 important signaling
pathways contributing to carcinogenesis.31 These biological
actions of insulin may partly explain our findings, with elevated
levels of fasting insulin having been implicated in tumor
progression and proliferation in breast cancer patients.32,33
Accordingly, our study cohort with IR harbored larger tumors
and had elevated Ki-67, suggesting that IR could be a useful
prognostic marker. However, the usefulness of IR as a prog-
nostic marker requires further independent validation, including
confirmation of a correlation between IR and survival in
patients with breast cancer.
In the present study, IR was associated with menopausal
status in patients with breast cancer. Menopause, which
involves hormonal changes, can affect IR.11 The major endo-
crine change during menopause is a decrease in endogenous
Breast Cancer Patients With Insulin Resistanceestradiol levels, which leads to excess androgen. This change in
hormonal balance possibly contributes to an increase in visceral
adiposity, which is related with IR in postmenopausal women,34
www.md-journal.com | 3
TABLE 1. Mean Insulin, Glucose, and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) According to Clinico-
pathological Factors
Insulin Glucose HOMA-IR
Characteristic MeanSD P Value MeanSD P Value MeanSD P Value
Age, y
50 (n¼ 410) 6.49 4.59 0.01 94.92 8.56 <0.001 1.56 1.21 0.004
>50 (n¼ 350) 7.47 5.81 97.96 9.42 1.85 1.55
Menopausal status
Premenopausal (n¼ 391) 6.44 4.59 0.007 94.52 8.38 <0.001 1.54 1.21 0.002
Postmenopausal (n¼ 369) 7.47 5.74 98.23 9.42 1.85 1.53
BMI, kg/m2
<25 (n¼ 572) 6.19 4.71 <0.001 95.72 8.78 0.001 1.50 1.23 <0.001
25 (n¼ 188) 9.23 5.94 98.15 9.76 2.29 1.62
Tumor size
1 cm (n¼ 315) 6.28 3.92 0.002 95.27 8.72 0.007 1.50 1.01 0.001
>1 cm (n¼ 445) 7.41 5.91 97.07 9.27 1.82 1.58
Tumor stage
Tis (n¼ 120) 6.24 4.29 0.06 93.64 8.05 0.006 1.47 1.09 0.03
T1a (n¼ 67) 6.22 3.90 95.81 9.01 1.50 1.03
T1b (n¼ 128) 6.34 3.58 96.51 9.00 1.53 0.92
T1c (n¼ 274) 7.30 5.85 96.76 9.25 1.79 1.55
T2–3 (n¼ 171) 7.59 6.01 97.57 9.30 1.88 1.63
Node stage
N0 (n¼ 618) 6.78 4.57 0.02 96.48 9.26 0.21 1.65 1.21 0.02
N1 (n¼ 122) 7.28 7.06 95.17 7.96 1.76 1.85
N2–3 (n¼ 20) 9.94 8.74 98.30 9.79 2.50 2.50
TNM Stage
Stage 0 (n¼ 120) 6.24 4.29 0.03 93.64 8.05 0.005 1.47 1.09 0.02
Stage 1 (n¼ 392) 6.75 4.47 96.90 9.36 1.65 1.18
Stage 2 (n¼ 225) 7.42 6.27 96.58 8.89 1.81 1.66
Stage 3 (n¼ 23) 9.27 8.33 97.96 9.22 2.32 2.37
Histologic grade
I/II (n¼ 605) 6.88 5.29 0.50 96.00 9.02 0.05 1.67 1.40 0.40
III (n¼ 155) 7.20 4.87 97.59 9.24 1.77 1.29
ER
Negative (n¼ 178) 7.04 5.29 0.76 96.93 8.42 0.31 1.72 1.35 0.74
Positive (n¼ 582) 6.98 5.40 96.14 9.28 1.68 1.39
PR
Negative (n¼ 330) 7.05 5.45 0.61 97.28 9.01 0.01 1.72 1.41 0.57
Positive (n¼ 430) 6.86 5.02 95.59 9.09 1.67 1.36
HER-2
Negative (n¼ 603) 7.04 5.31 0.29 96.24 9.13 0.63 1.72 1.43 0.30
Positive (n¼ 157) 6.55 4.77 96.64 8.94 1.59 1.18
Ki-67 (%)
<14 (n¼ 461) 6.72 4.84 0.05 95.95 9.29 0.11 1.63 1.29 .04
14 (n¼ 271) 7.52 5.86 97.07 8.89 1.85 1.55
Subtype
Luminal A (n¼ 405) 6.62 4.67 0.01 95.72 9.13 0.28 1.60 1.26 0.01
Luminal B/HER-2-negative (n¼ 95) 8.63 7.40 96.95 9.29 2.12 1.98
Luminal B/HER-2-positive (n¼ 83) 6.34 5.54 97.13 9.92 1.55 1.04
HER-2-positive (n¼ 74) 6.79 5.54 96.08 7.73 1.63 1.32
Triple-negative (n¼ 103) 7.26 5.14 97.63 8.85 1.80 1.38
BMI¼ body mass index, ER¼ estrogen receptor, HER-2¼ human epidermal growth factor receptor-2, HOMA-IR¼ homeostatic model assess-
ment of insulin resistance, PR¼ progesterone receptor, SD¼ standard deviation, TNM¼ tumor, node, metastasis.
Nam et al Medicine  Volume 95, Number 9, March 2016
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TABLE 2. Relationships Between Insulin Resistance and Clin-
icopathological Factors
Insulin Resistance
Characteristic
Absent
(n¼ 559, %)
Present
(n¼ 201, %)
P
Value
Age, y
50 323 (57.8) 87 (43.3) 0.001
>50 236 (42.2) 114 (56.7)
Menopausal status
Premenopausal 310 (55.5) 81 (40.3) <0.001
Postmenopausal 249 (44.5) 120 (59.7)
BMI, kg/m2
<25 458 (81.9) 114 (56.7) <0.001
25 101 (18.1) 87 (43.3)
Tumor size, cm
1 245 (43.8) 70 (34.8) 0.03
>1 314 (56.2) 131 (65.2)
Nodal status
Negative 456 (81.6) 162 (80.6) 0.83
Positive 103 (18.4) 39 (19.4)
TNM stage
Stage 0 96 (17.2) 24 (11.9) 0.18
Stage 1 287 (51.3) 105 (52.2)
Stage 2–3 176 (31.5) 72 (35.8)
Histologic grade
I/II 455 (81.4) 150 (74.6) 0.04
III 104 (18.6) 51 (25.4)
ER
Negative 130 (23.3) 48 (23.9) 0.92
Positive 429 (76.7) 153 (76.1)
PR
Negative 241 (43.1) 89 (44.3) 0.80
Positive 318 (56.9) 112 (55.7)
HER-2
Negative 442 (79.1) 161 (80.1) 0.76
Positive 117 (20.9) 40 (19.9)
Ki-67 (%, n¼ 732)
<14 354 (66.2) 107 (54.3) 0.003
14 181 (33.8) 90 (45.7)
Subtype
Luminal A 312 (55.8) 93 (46.3) 0.01
Luminal B/HER-
2-negative
56 (10.0) 39 (19.4)
Luminal B/HER-
2-positive
62 (11.1) 21 (10.4)
HER-2-positive 55 (9.8) 19 (9.5)
Triple-negative 74 (13.2) 29 (14.4)
BMI¼ body mass index, ER¼ estrogen receptor, HER-2¼ human
TABLE 3. Multivariate Logistic Regression Analysis of Factors
Related to Insulin Resistance
95% CI
Variable OR Lower Upper P Value
Menopausal status
Premenopausal Ref.
Postmenopausal 1.717 1.214 2.428 0.002
BMI, kg/m2
<25 Ref.
25 3.041 2.115 4.370 <0.001
Tumor size, cm
1 Ref.
>1 1.201 0.821 1.756 0.35
Nodal status
Negative Ref.
Positive 0.913 0.576 1.448 0.70
Histologic grade
I/II Ref.
III 1.292 0.782 2.132 0.32
Subtype
Luminal A Ref.
Luminal B/HER-2-negative 1.881 1.127 3.138 0.02
Luminal B/HER-2-positive 0.941 0.521 1.700 0.84
HER-2-positive 0.833 0.427 1.625 0.59
Triple-negative 0.967 0.533 1.752 0.91
Medicine  Volume 95, Number 9, March 2016 Breast Cancer Patients With Insulin Resistanceas observed in this study. This hormonal change can affect
breast cancer pathophysiology,35 which is consistent with our
findings that menopause was an independent risk factor for IR.
Therefore, we conducted a subgroup analysis to evaluate the
differences in clinicopathological characteristics according to
epidermal growth factor receptor-2, PR¼ progesterone receptor,
TNM¼ tumor, node, metastasis.menopausal status.
This subgroup analysis by menopausal status showed more
clear associations between clinicopathological characteristics
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.and IR among postmenopausal patients. Obesity, higher tumor
burden, and the luminal B/HER-2-negative subtype were inde-
pendently associated with IR in postmenopausal but not pre-
menopausal breast cancer patients. Menopause, which involves
specific hormonal changes, can affect the association between
insulin resistance and breast cancer. The major source of
estrogen in postmenopausal women is estrone, which is a
product of the aromatization of androstenedione, formed by
aromatase. This hormonal change may contribute to the
increase in visceral adiposity related with IR in postmenopausal
women, as observed in this study. It has been demonstrated that
adipocyte-secreted factors can directly promote mammary
tumorigenesis through induction of antiapoptotic transcriptional
programs and proto-oncogene stabilization.36 These findings
could facilitate the identification of subgroups that might
benefit from targeted treatments aimed specifically at over-
coming IRmechanisms. Prospective and randomized controlled
trials to evaluate the direct antitumor effect of metformin in
nondiabetic postmenopausal women with ER-positive breast
cancer are ongoing,37 and the results of such clinical trials are
highly anticipated to expand the current insights in the
near future.
Unexpectedly, in our premenopausal patients, IR was not
associated with traditional prognostic factors, except for BMI.
This finding might suggest a differential action of IR on tumor
biology in premenopausal patients with breast cancer, partly
consistent with previously reported findings.38,39 Further inves-
tigations are required to clarify a differential metabolic action of
BMI¼ body mass index, CI¼ confidence interval, HER-2¼ human
epidermal growth factor receptor-2, OR¼ odds ratio.insulin on tumor progression in premenopausal patients.
This study has several limitations. First, our findings are
derived from retrospective data obtained at a single institution.
www.md-journal.com | 5
expression for clinical relevance and found a differential associ-
TABLE 4. Relationships Between Insulin Resistance and Clinicopathological Factors Stratified by Menopausal Status
Premenopausal (n¼ 391) Postmenopausal (n¼ 369)
Insulin Resistance Insulin Resistance
Characteristic
Absent
(n¼ 310, %)
Present
(n¼ 81, %)
P
Value
Absent
(n¼ 249, %)
Present
(n¼ 120, %)
P
Value
Age, y
MeanSD 43.35 5.38 43.93 5.65 0.40 58.38 7.80 60.90 8.36 0.005
BMI, kg/m2
<25 268 (86.5) 45 (55.6) <0.001 190 (76.3) 69 (57.5) <0.001
25 42 (13.5) 36 (44.4) 59 (23.7) 51 (42.5)
Tumor size, cm
1 126 (40.6) 36 (44.4) 0.61 119 (47.8) 34 (28.3) <0.001
>1 184 (59.4) 45 (55.6) 130 (52.2) 86 (71.7)
Nodal status
Negative 251 (81.0) 69 (85.2) 0.42 205 (82.3) 93 (77.5) 0.33
Positive 59 (19.0) 12 (14.8) 44 (17.7) 27 (22.5)
TNM Stage
Stage 0 52 (16.8) 11 (13.6) 0.14 44 (17.7) 13 (10.8) 0.01
Stage 1 153 (49.4) 50 (61.7) 134 (53.8) 55 (45.8)
Stage 2–3 105 (33.9) 20 (24.7) 71 (28.5) 52 (43.3)
Histologic grade
I/II 265 (85.5) 64 (79.0) 0.17 190 (76.3) 86 (71.7) 0.37
III 45 (14.5) 17 (21.0) 59 (23.7) 34 (28.3)
ER
Negative 46 (14.8) 17 (21.0) 0.23 84 (33.7) 31 (25.8) 0.15
Positive 264 (85.2) 64 (79.0) 165 (66.3) 89 (74.2)
PR
Negative 84 (27.1) 23 (28.4) 0.89 157 (63.1) 66 (55.0) 0.14
Positive 226 (72.9) 58 (71.6) 92 (36.9) 54 (45.0)
HER-2
Negative 262 (84.5) 62 (76.5) 0.10 180 (72.3) 99 (82.5) 0.04
Positive 48 (15.5) 19 (23.5) 69 (27.7) 21 (17.5)
Ki-67 (%, n¼ 732)
<14 196 (67.4) 49 (61.3) 0.35 158 (64.8) 58 (49.6) 0.006
14 95 (32.6) 31 (38.8) 86 (35.2) 59 (50.4)
Subtype
Luminal A 191 (61.6) 42 (51.9) 0.16 121 (48.6) 51 (42.5) <0.001
Luminal B/HER-2-negative 41 (13.2) 13 (16.0) 15 (6.0) 26 (21.7)
Luminal B/HER-2-positive 32 (10.3) 9 (11.1) 30 (12.0) 12 (10.0)
HER-2-positive 16 (5.2) 10 (12.3) 39 (15.7) 9 (7.5)
Triple-negative 30 (9.7) 7 (8.6) 44 (17.7) 22 (18.3)
derm
Nam et al Medicine  Volume 95, Number 9, March 2016Second, the gold standard to measure IR is the euglycemic
glucose clamp;40 however, this method is impractical as it is
labor- and time-intensive. Hence, we used the HOMA-IR as a
surrogate for the state of IR in the present study. HOMA-IR has
been observed to have a linear correlation with the euglycemic
glucose clamp in various studies and is widely considered the
most appropriate and extensively validated surrogate for the
state of IR.41,42 Third, the study period was too short to assess
the impact of IR as a prognostic factor in patients with breast
cancer. This study relied on 1-time measurements of glucose,
insulin, and HOMA-IR, which may only have a low ability to
BMI¼ body mass index, ER¼ estrogen receptor, HER-2¼ human epi
deviation, TNM¼ tumor, node, metastasis.characterize a person’s long-term insulin resistance along the
progression and development of breast cancer. Therefore, we
plan to evaluate the prognostic function of IR in the near future,
6 | www.md-journal.comusing long-term retrospective data. However, despite the limita-
tions of this study, there are also several strengths. We inves-
tigated the clinicopathological factors related to IR among
newly diagnosed Asian patients with breast cancer. In particu-
lar, we examined the effects of breast cancer subtypes and Ki-67
al growth factor receptor-2, PR¼ progesterone receptor, SD¼ standardation of well-known prognostic factors with IR according to
menopausal status.
CONCLUSIONS
In conclusion, IRwas significantly associated with obesity,
tumor proliferation, and luminal B subtype breast cancers in
postmenopausal women. In premenopausal patients, IR was
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 5. Multivariate Logistic Regression Analyses of Factors Related to Insulin Resistance by Menopausal Status
Premenopausal Postmenopausal
OR
95% CI 95% CI
Variable Lower Upper P Value OR Lower Upper P Value
BMI, kg/m2
<25 Ref. Ref.
25 5.319 2.991 9.459 <0.001 1.998 1.225 3.258 0.006
Tumor size, cm
1 Ref. Ref.
>1 0.648 0.365 1.153 0.14 1.832 1.079 3.110 0.03
Nodal status
Negative Ref. Ref.
Positive 0.737 0.344 1.579 0.43 1.050 0.566 1.947 0.88
Histologic grade
I/II Ref. Ref.
III 1.170 0.523 2.614 0.70 1.338 0.681 2.626 0.40
Subtype
Luminal A Ref. Ref.
Luminal B/HER-2-negative 1.417 0.651 3.084 0.38 2.968 1.392 6.326 0.005
Luminal B/HER-2-positive 0.995 0.407 2.429 0.99 0.830 0.373 1.847 0.65
HER-2-positive 1.883 0.675 5.248 0.23 0.505 0.201 1.266 0.15
Triple-negative 0.891 0.315 2.520 0.83 0.934 0.438 1.991 0.86
BMI¼ body mass index, CI¼ confidence interval, HER-2¼ human epidermal growth factor receptor-2, OR¼ odds ratio.
Medicine  Volume 95, Number 9, March 2016 Breast Cancer Patients With Insulin Resistanceonly associated with obesity. These findings suggest that IR
might be a factor in determining prognosis in postmenopausal
breast cancer and that it might facilitate the identification of
subgroups that could benefit from targeted treatments to over-
come IR mechanisms. Additional studies are needed to evaluate
the prognosis of patients with IR and to clarify the exact role of
insulin signaling pathways in patients with breast cancer,
including the differential metabolic actions according to
menopausal status.
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